APE1/Ref-1 as a Serological Biomarker for the Detection of Bladder Cancer

• Published in: Cancer research and treatment Vol. 47; no. 4; pp. 823 - 833
• Main Authors: Shin, Ju Hyun, Choi, Sunga, Lee, Yu Ran, Park, Myoung Soo, Irani, Kaikobad, Lee, Sang Do, Park, Jin Bong, Kim, Jin Man, Lim, Jae Sung, Jeon, Byeong Hwa
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Cancer Association 01.10.2015; 대한암학회
• Subjects: Aged; Biomarkers, Tumor - blood; DNA-(Apurinic or Apyrimidinic Site) Lyase - blood; DNA-(Apurinic or Apyrimidinic Site) Lyase - genetics; DNA-(Apurinic or Apyrimidinic Site) Lyase - metabolism; Female; Humans; Male; Middle Aged; Original; Sensitivity and Specificity; Serologic Tests; Urinary Bladder Neoplasms - blood; Urinary Bladder Neoplasms - diagnosis; 의약학; Apurinic/apyrimidinic endonuclease 1/redox factor-1; Urinary bladder neoplasms; Biological markers; Enzyme-linked immunosorbent assay
• ISSN: 1598-2998; 2005-9256; 2005-9256
• DOI: 10.4143/crt.2014.074

Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) is a multifunctional protein that shows elevated expression in a number of cancers. We attempted to determine whether serum APE1/Ref-1 is elevated in patients with bladder cancer. Serum APE1/Ref-1 levels were determined using enzyme-linked immunosorbent assay in serum from patients with bladder cancer who had not received chemotherapy or radiotherapy (n=51) and non-tumor controls (n=55). The area under the receiver operating characteristic area under the curve was applied to determine the correlation between clinical factors and the serum levels of APE1/Ref-1. Serum levels of APE1/Ref-1 in bladder cancer patients were significantly elevated compared to those of the control group (3.548 ± 0.333 ng/100 μL [n=51] for bladder cancer vs. 1.547 ± 0.319 ng/100 μL [n=55] for the control group), with a sensitivity and specificity of 93% and 59%, respectively. Serum APE1/Ref-1 levels are associated with tumor stage, grade, muscle invasion, and recurrence. Serum APE1/Ref-1 might be useful as a potential serologic biomarker for bladder cancer.